Claims for Patent: 8,461,169

Summary for Patent: 8,461,169

Title:	Compounds modulating c-fms and/or c-kit activity
Abstract:	Compounds active on the receptor protein tyrosine kinases c-kit and/or c-fms are provided herewith. Also provided herewith are compositions useful for treatment of c-kit mediated diseases or conditions and/or c-fms-mediated diseases or conditions, and methods for the use thereof.
Inventor(s):	Zhang; Jiazhong (Burlingame, CA), Ibrahim; Prabha N. (Mountain View, CA), Artis; Dean R. (Kensington, CA), Bremer; Ryan (Emeryville, CA), Wu; Guoxian (Palo Alto, CA), Zhu; Hongyao (Waterford, CT), Nespi; Marika (Berkeley, CA), Zhang; Chao (Moraga, CA)
Assignee:	Plexxikon Inc. (Berkeley, CA)
Application Number:	12/958,379
Patent Claims:	1. A method for treating a subject suffering from disease or condition mediated by an increase in c-kit and/or c-fms kinase activity, said method comprising administering to the subject an effective amount of a compound of Formula III, ##STR00925## or a salt, prodrug, tautomer, or stereoisomer thereof, wherein: L.sub.4 is --CH.sub.2--, or --C(O)--; R.sup.81 is selected from the group consisting of hydrogen, --CN, fluoro, chloro, lower alkyl, fluoro substituted lower alkyl, lower alkoxy, and fluoro substituted lower alkoxy; R.sup.82 is hydrogen; R.sup.83 is nitrogen containing heteroaryl, wherein nitrogen containing heteroaryl is optionally substituted with one or two substituents selected from the group consisting of halogen, lower alkyl, fluoro substituted lower alkyl, cycloalkylamino, --NHR.sup.41, --NR.sup.41R.sup.41, --OR.sup.41 and --S(O).sub.2R.sup.41; and R.sup.41 at each occurrence is lower alkyl or cycloalkyl, wherein lower alkyl is optionally substituted with one or more fluoro. 2. The method of claim 1, wherein said compound is selected from the group consisting of: Pyridin-3-ylmethyl-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]- -amine, 2,5-Dimethyl-2H-pyrazole-3-carboxylic acid [5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amide, (3-Chloro-pyridin-4-ylmethyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-py- ridin-2-yl]-amine, (2-Methoxy-pyridin-3-ylmethyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-p- yridin-2-yl]-amine, (6-Methoxy-pyridin-2-ylmethyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-p- yridin-2-yl]-amine, (3,5-Dichloro-pyridin-4-ylmethyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl- )-pyridin-2-yl]-amine, (6-Morpholin-4-yl-pyridin-2-ylmethyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylme- thyl)-pyridin-2-yl]-amine, (5-Fluoro-pyridin-3-ylmethyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-py- ridin-2-yl]-amine, (3-Chloro-pyridin-4-ylmethyl)-[5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylm- ethyl)-pyridin-2-yl]-amine, (6-Methoxy-pyridin-3-ylmethyl)-[5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl- methyl)-pyridin-2-yl]-amine, 2-Methoxy-N-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-isonic- otinamide, N-[5-(1H-Pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-isonic- otinamide, Pyrazine-2-carboxylic acid [5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amide, 6-Methyl-N-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-nicotin- amide, 2-Chloro-N-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-i- sonicotinamide, (1-Methyl-1H-imidazol-4-ylmethyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl- )-pyridin-2-yl]-amine, (1,5-Dimethyl-1H-pyrazol-3-ylmethyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmet- hyl)-pyridin-2-yl]-amine, (3-Bromo-pyridin-4-ylmethyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyr- idin-2-yl]-amine, (1H-Benzoimidazol-2-ylmethyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-py- ridin-2-yl]-amine, (3-Fluoro-pyridin-2-ylmethyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-py- ridin-2-yl]-amine, 3-{6-[(2-Methoxy-pyridin-3-ylmethyl)-amino]-pyridin-3-ylmethyl}-1H-pyrrol- o[2,3-b]pyridine-5-carbonitrile, [5-(5-Fluoro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-methox- y-pyridin-3-ylmethyl)-amine, (6-Methoxy-pyridin-3-ylmethyl)-[5-(5-methoxy-1H-pyrrolo[2,3-b]pyridin-3-y- lmethyl)-pyridin-2-yl]-amine, (2-Morpholin-4-yl-pyridin-3-ylmethyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylme- thyl)-pyridin-2-yl]-amine, Dimethyl-(5-{[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-ylamino]-- methyl}-pyrimidin-2-yl)-amine, (5-Fluoro-pyridin-2-ylmethyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-py- ridin-2-yl]-amine, (2,6-Dimethoxy-pyridin-3-ylmethyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethy- l)-pyridin-2-yl]-amine, (6-Cyclopentyloxy-pyridin-3-ylmethyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylme- thyl)-pyridin-2-yl]-amine, [6-Fluoro-5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-methox- y-pyridin-3-ylmethyl)-amine, [5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-6-fluoro-pyridin-2-yl]-- (6-methoxy-pyridin-3-ylmethyl)-amine, Pyrimidin-5-ylmethyl-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-y- l]-amine, 2,2-Dimethyl-N-(3-{[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyri- din-2-ylamino]-methyl}-pyridin-2-yl)-propionamide, Methyl-(3-{[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-ylamino]-me- thyl}-pyridin-2-yl)-amine, Methyl-(5-{[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-ylamino]-me- thyl}-pyrimidin-2-yl)-amine, Dimethyl-(3-{[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-ylamino]-- methyl}-pyridin-2-yl)-amine, (5-Chloro-pyridin-3-ylmethyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-py- ridin-2-yl]-amine, [5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-triflu- oromethyl-pyridin-3-ylmethyl)-amine, and [5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-[6-(2,2,2- -trifluoro-ethoxy)-pyridin-3-ylmethyl]-amine, or a salt or tautomer thereof. 3. The method of claim 1, wherein said compound is pyridine-2-carboxylic acid [5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amide, or a pharmaceutically acceptable salt thereof. 4. The method of claim 1, wherein said compound is 5-methyl-pyrazine-2-carboxylic acid [5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amide, or a pharmaceutically acceptable salt thereof. 5. The method of claim 1, wherein said compound is [5-(5-chloro-1H-pyrrolo[2, 3-1)]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-trifluoromethyl-pyridin-3-ylmet- hyl)-amine, or a pharmaceutically acceptable salt thereof. 6. The method of claim 1, wherein said compound is [5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-trifluoromethyl- -pyridin-3-ylmethyl)-amine, or a pharmaceutically acceptable salt thereof. 7. The method of claim 1, wherein said compound is (1-methyl-1H-benzoimidazol-2-ylmethyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylm- ethyl)-pyridin-2-yl]-amine, or a pharmaceutically acceptable salt thereof. 8. The method of claim 1, wherein said compound is (6-methoxy-pyridin-3-ylmethyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-p- yridin-2-yl]-amine, or a pharmaceutically acceptable salt thereof. 9. The method of claim 1, wherein said compound is (5-methoxy-pyridin-3-ylmethyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-p- yridin-2-yl]-amine, or a pharmaceutically acceptable salt thereof. 10. The method of claim 1, wherein said compound is (3-fluoro-pyridin-4-ylmethyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-py- ridin-2-yl]-amine, or a pharmaceutically acceptable salt thereof. 11. The method of claim 1, wherein said compound is 3-{6-[(3-chloro-pyridin-4-ylmethyl)-amino]-pyridin-3-ylmethyl}-1H-pyrrolo- [2,3-b]pyridine-5-carbonitrile, or a pharmaceutically acceptable salt thereof. 12. The method of claim 1, wherein said compound is 3-{6-[(6-trifluoromethyl-pyridin-3-ylmethyl)-amino]-pyridin-3-ylmethyl}-1- H-pyrrolo[2,3-b]pyridine-5-carbonitrile, or a pharmaceutically acceptable salt thereof. 13. The method of claim 1, wherein said compound is [5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-methox- y-pyridin-3-ylmethyl)-amine, or a pharmaceutically acceptable salt thereof. 14. The method of claim 1, wherein said compound is 3-{6-[(6-methoxy-pyridin-3-ylmethyl)-amino]-pyridin-3-ylmethyl}-1H-pyrrol- o[2,3-b]pyridine-5-carbonitrile, or a pharmaceutically acceptable salt thereof. 15. The method of claim 1, wherein said compound is (2-methoxy-pyridin-3-ylmethyl)-[5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl- methyl)-pyridin-2-yl]-amine, or a pharmaceutically acceptable salt thereof. 16. The method of claim 1, wherein said compound is [5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(2-methox- y-pyridin-3-ylmethyl)-amine, or a pharmaceutically acceptable salt thereof. 17. The method of claim 1, wherein said compound is [5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(5-fluoro- -pyridin-3-ylmethyl)-amine, or a pharmaceutically acceptable salt thereof. 18. The method of claim 1, wherein said compound is [5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-[2-(2,2,2-trifluor- o-ethoxy)-pyridin-3-ylmethyl]-amine, or a pharmaceutically acceptable salt thereof. 19. The method of claim 1, wherein said compound is (2-methoxy-pyrimidin-5-ylmethyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)- -pyridin-2-yl]-amine, or a pharmaceutically acceptable salt thereof. 20. The method of claim 1, wherein the disease or condition is selected from the group consisting of mast cell tumors, small cell lung cancer, testicular cancer, gastrointestinal stromal tumors, glioblastoma, astrocytoma, neuroblastoma, carcinomas of the female genital tract, sarcomas of neuroectodermal origin, colorectal carcinoma, carcinoma in situ, Schwann cell neoplasia associated with neurofibromatosis, acute myeloid leukemia, acute lymphocytic leukemia, chronic myelogenous leukemia, multiple myeloma, mastocytosis, melanoma, breast cancer, ovarian cancer, prostate cancer, canine mast cell tumors, metastatic cancer, metastasis of cancer to bone or other tissues, chronic myeloproliferative diseases, myelofibrosis, renal hypertrophy, asthma, rheumatoid arthritis, allergic rhinitis, multiple sclerosis, osteoarthritis, inflammatory bowel syndrome, transplant rejection, systemic lupus erythematosis, ulcerative colitis, Crohn's disease, chronic obstructive pulmonary disease, emphysema, Kawasaki's Disease, hemophagocytic syndrome, multicentric reticulohistiocytosis, atherosclerosis, Type I diabetes, Type II diabetes, insulin resistance, hyperglycemia, obesity, lipolysis, hypereosinophilia, osteoporosis, increased risk of fracture, Paget's disease, hypercalcemia, osteomyelitis, peri-prosthetic or wear-debris-mediated osteolysis, endometriosis, glomerulonephritis, interstitial nephritis, Lupus nephritis, tubular necrosis, diabetic nephropathy, stroke, Alzheimer's disease, Parkinson's disease, inflammatory pain, chronic pain, and bone pain. 21. The method of claim 1, wherein the disease is a cancer, metastatic cancer, glioblastoma, systemic lupus erythematosis, Lupus nephritis, breast cancer or rheumatoid arthritis. 22. The method of claim 2, wherein the disease is a cancer, metastatic cancer, glioblastoma, systemic lupus erythematosis, Lupus nephritis, breast cancer or rheumatoid arthritis. 23. The method of claim 21, wherein the method further comprises administering one or more chemotherapeutic agents. 24. The method of claim 23, wherein the compound and said one or more agents are administered simultaneously, separately or sequentially. 25. The method of claim 22, wherein the method further comprises administering one or more chemotherapeutic agents. 26. The method of claim 25, wherein the compound and said one or more agents are administered simultaneously, separately or sequentially. 27. The method of claim 21, wherein the method further comprises administering one or more chemotherapeutic agents selected from the list consisting of an alkylating agent, an antibiotic, a hormone or hormone antagonist, a taxane, an antiangiogenic agent, a kinase inhibitor, a targeted signal transduction inhibitor, a biological response modifier, and other chemotherapeutics. 28. The method of claim 22, wherein the method further comprises administering one or more chemotherapeutic agents selected from the list consisting of an alkylating agent, an antibiotic, a hormone or hormone antagonist, a taxane, an antiangiogenic agent, a kinase inhibitor, a targeted signal transduction inhibitor, a biological response modifier, and other chemotherapeutics. 29. The method of claim 21, wherein the method further comprises administering a taxane. 30. The method of claim 22, wherein the method further comprises administering a taxane. 31. The method of claim 21, wherein the method further comprises administering paclitaxel or DHA-paclitaxel. 32. The method of claim 22, wherein the method further comprises administering paclitaxel or DHA-paclitaxel.